logo
NAMI MN Sue Abderholden to retire as executive director after 24 years

NAMI MN Sue Abderholden to retire as executive director after 24 years

Yahoo02-05-2025
After 24 years in her role, National Alliance on Mental Illness Minnesota's executive director Sue Abderholden is retiring.
Abderholden will remain in her role until Oct. 15, according to a release from the organization. The NAMI Minnesota of Directors will begin a leadership transition process in the next several months. It has formed a succession committee and retained the executive search firm Ballinger Leafblad, Inc.
When Abderholden began with the organization in 2001, it had two and half staff members and a $160,000 budget. Since that time, it has grown to 37 staffers and is a $3 million organization.
'Sue Abderholden's leadership has been nothing short of transformational,' said Jessica Gourneau, president of the NAMI Minnesota Board of Directors, in a statement. 'She has led NAMI Minnesota with vision, heart, and an unwavering commitment to those living with mental illnesses and their families. Because of Sue, our organization has grown in reach, reputation, and impact. Her fierce advocacy at the legislature, her strategic partnerships across sectors, and her tireless work to create culturally responsive, person-centered care have set the gold standard for mental health advocacy.'
Abderholden's advocacy has helped pass more than two dozen laws affecting education, healthcare, housing and criminal justice for people with mental illnesses, according to the organization. This has included advocating for laws requiring mental health training for teachers, getting mental health screenings for those entering jails, reforming the state's commitment laws to promote voluntary engagement in treatment, expanding crisis and early interventions services, the diversity of the workforce and strengthening mental health parity protections. She also worked to restrict the use of solitary confinement in prisons for people with mental illness.
Abderholden's work has been recognized with multiple awards, including the Minneapolis Health Department's Health Equity Award, Macalester College's Distinguished Citizen Award, the National NAMI Rona and Ken Purdy Award to End Discrimination, and multiple recognitions as one of Minnesota Physicians' '100 Most Influential Health Care Leaders.'
In addition to her work with NAMI Minnesota, Abderholden also has taught about health and mental health policy at the University of Minnesota's School of Social Work and served on several state advisory committees and task forces, according to the University.
'It has been the honor of a lifetime to be part of this movement,' Abderholden said in a statement. 'The people who courageously shared their stories, the families who organized for change, and the advocates who never gave up — they are the reason for our success. I am deeply grateful for the opportunity to have worked alongside so many incredible individuals to help build a better, more compassionate mental health system for Minnesota.'
Wilder East Clinic opens on St. Paul's East Side
Woman killed in St. Paul home, her 2-year-old found unharmed
State fines Regions Hospital for improper medical waste disposal
St. Paul police: 2nd grader said he brought gun to school to show friends
Metro State University lockdown prompted by man firing shots at his mother
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Centerline Biomedical Appoints Jim Dillon President and Chief Executive Officer
Centerline Biomedical Appoints Jim Dillon President and Chief Executive Officer

Associated Press

time17 hours ago

  • Associated Press

Centerline Biomedical Appoints Jim Dillon President and Chief Executive Officer

CLEVELAND--(BUSINESS WIRE)--Aug 18, 2025-- Centerline Biomedical, Inc. ('Centerline'), an innovative leader in cardiovascular navigation and visualization systems, announced the appointment of Jim Dillon as President and Chief Executive Officer (CEO) and a member of its board of directors. He will assume his responsibilities on August 18, 2025. Mr. Dillon succeeds Gulam Khan, who has served as CEO since October 2022. Mr. Khan led Centerline Biomedical through a period of portfolio development. During his tenure, Centerline Biomedical developed, received 510(k) clearance, and commercialized its second-generation devices and appreciable software advances. We appreciate Gulam's significant contributions. 'It is an honor to join Centerline at such a pivotal stage. The IOPS platform is poised for scaled growth and I am grateful to have the opportunity to lead the company as it continues to innovate such remarkable technology for patients and care givers,' said Mr. Dillon. 'With decades of med tech industry leadership, Jim brings deep cardiovascular sector experience leading portfolio innovation, operational alignment, and strategic financing for med tech companies,' said Todd Schwarzinger, Centerline's Chairman. 'Jim has a strong track record of driving commercial growth through category creation and market penetration and we are excited to have him leading Centerline.' Mr. Dillon has previously served as President and CEO for cardiovascular innovation companies; BiVACOR, BioVentrix, Reprieve Cardiovascular and Renal Guard Solutions. To learn more about the IOPS platform, visit About Centerline Biomedical Founded in 2015, Centerline Biomedical, Inc. is headquartered in Cleveland, Ohio. The company's commercially available platform, IOPS® (Intra-Operative Positioning System), enables improved visualization and device navigation, while protecting patient and healthcare provider exposure from the harmful effects of fluoroscopic X-ray radiation during standard interventions. The company is a Cleveland Clinic Innovations spin-off investing in commercialization and development of technology to improve image guidance and reduce the need for fluoroscopic x-ray during transcatheter procedures. IOPS is indicated for use in the peripheral, aortic and aortic side branch vasculature. The IOPS platform consists of a mobile cart powered by proprietary visualization software and intelligent, sensorized IOPS catheters and guidewires. Visit for more information. View source version on CONTACT: For inquiries, please contact: Patty Burns, SVP Marketing Centerline Biomedical, Inc. Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA OHIO INDUSTRY KEYWORD: CARDIOLOGY SOFTWARE RADIOLOGY HEALTH MEDICAL DEVICES HOSPITALS HEALTH TECHNOLOGY TECHNOLOGY SOURCE: Centerline Biomedical, Inc. Copyright Business Wire 2025. PUB: 08/18/2025 11:00 AM/DISC: 08/18/2025 11:00 AM

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

Business Upturn

time18 hours ago

  • Business Upturn

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the first and only therapy approved in the European Union (EU) to treat desmoid tumors. 'Desmoid tumors can have a profound impact on people's lives and are difficult to manage due to their invasive nature and high rates of recurrence. Until now, there have been no approved medicines in Europe,' said Bernd Kasper, M.D., Ph.D., Professor, University of Heidelberg, Mannheim Cancer Center, Mannheim, Germany, and principal investigator of the DeFi trial. 'OGSIVEO is a highly innovative therapy with efficacy data demonstrating both meaningful antitumor activity and a significant improvement in desmoid tumor symptoms, including a significant reduction in pain which is the most debilitating symptom reported by patients.' 'This approval is a long-awaited advance for desmoid tumor patients, their families and physicians in Europe,' said Lynne Hernandez, Executive Director of the Desmoid Tumor Research Foundation. 'It is our hope that patients will benefit from greater awareness of desmoid tumors, faster diagnoses, and better outcomes now that there is an approved treatment.' Desmoid tumors are rare, locally aggressive tumors that form in the connective tissues of the body.1,2 Approximately 1,300 to 2,300 new cases of desmoid tumors are diagnosed annually in the EU.3,4,5 These tumors can cause severe pain, limited function, loss of mobility, disfigurement and fatigue.1,6-10 They are challenging to manage because of their unpredictable nature and high rate of recurrence, which can significantly impact an individual's quality of life.2,7,8,11,12 Desmoid tumor experts and treatment guidelines now recommend medical therapy as first-line intervention instead of surgery for most tumor locations requiring treatment.13,14 'We would like to extend our gratitude to the patients, families, investigators, and advocacy organizations who helped make this EC approval possible,' said Danny Bar-Zohar, MD, CEO of Healthcare and Executive Board Member at Merck KGaA, Darmstadt, Germany. 'OGSIVEO is already established as the standard of care systemic therapy for desmoid tumors in the U.S., and our goal is to bring the same treatment benefits to patients in Europe. Following last month's EC approval of our therapy for patients with NF1-PN, we are in the unique position of launching two innovative treatments — underscoring our commitment to the rare tumor patient community.' The EC approval of OGSIVEO is based on results from the Phase 3 DeFi trial, which enrolled 142 adult patients with progressing desmoid tumors and met the primary endpoint of improving progression-free survival (PFS). OGSIVEO demonstrated a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). OGSIVEO also demonstrated a significant improvement in objective response rate (ORR). The confirmed ORR based on RECIST v1.1 was 41% with OGSIVEO versus 8% with placebo (p<0.001); the complete response rate was 7% in the OGSIVEO arm and 0% in the placebo arm. The median time to first response was 5.6 months with OGSIVEO and 11.1 months with placebo. Additionally, OGSIVEO demonstrated early and sustained improvement in patient-reported outcomes (PROs), including pain (p<0.001), desmoid tumor-specific symptoms (p<0.001), physical/role functioning (p<0.001), and overall health-related quality of life (p≤0.01).13 OGSIVEO exhibited a manageable safety and tolerability profile. The most common adverse reactions reported in 88 patients receiving OGSIVEO across all studies (69 patients from DeFi and 19 patients from early phase studies) were diarrhoea (85%), rash (65%), ovarian toxicity in women of childbearing potential (60%) nausea (59%), fatigue (50%), hypophosphataemia (50%), headache (40%) and stomatitis (40%).13 About the DeFi Trial DeFi (NCT03785964) was a global, randomized (1:1), multicenter, double-blind, placebo-controlled pivotal Phase 3 trial that evaluated the efficacy, safety and tolerability of nirogacestat in adult patients with progressing desmoid tumors. The double-blind phase of the study randomized 142 patients (nirogacestat, n=70; placebo n=72) to receive 150 mg of nirogacestat or placebo twice daily. Key eligibility criteria included tumor progression by ≥20% as measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) within 12 months prior to screening. The primary endpoint was progression-free survival, as assessed by blinded independent central review, or death by any cause. Secondary and exploratory endpoints included safety and tolerability measures, objective response rate, duration of response, changes in tumor volume assessed by magnetic resonance imaging (MRI), and changes in patient-reported outcomes. DeFi also included an open-label extension phase. About Desmoid Tumors Desmoid tumors are rare, locally aggressive tumors of the soft tissues that can be serious, debilitating, and, in rare cases when vital structures are impacted, life-threatening.1,2 Desmoid tumors are most commonly diagnosed in patients between the ages of 20 and 44 years, with a two-to-three times higher prevalence in females.3,11 It is estimated that there are 1,300-2,300 new desmoid tumor cases diagnosed per year in the European Union. 3,4,5 Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical resection.11,12 Desmoid tumor experts and treatment guidelines now recommend systemic therapies as first-line intervention for most tumor locations requiring treatment.14,15 About OGSIVEO® (nirogacestat) OGSIVEO® (nirogacestat) is an oral, selective, small molecule gamma secretase inhibitor approved in the United States and European Union as monotherapy for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The FDA and the EMA have granted Orphan Drug designation for OGSIVEO for the treatment of desmoid tumors. For the full list of side effects and restrictions with OGSIVEO, see the full Summary of Product Characteristics. IMPORTANT SAFETY INFORMATION Diarrhoea Diarrhoea was reported in patients receiving nirogacestat. Patients who experience diarrhoea during treatment with nirogacestat should be monitored and managed using anti‑diarrhoeal medicinal products. For Grade 3 diarrhoea that persists for ≥ 3 days despite maximal medical therapy, nirogacestat should be withheld until diarrhoea is resolved to Grade ≤ 1 or baseline, then it should be restarted at 100 mg twice daily. Skin and subcutaneous tissue disorders Dermatologic reactions, including maculopapular rash, folliculitis, and hidradenitis, were reported in patients receiving nirogacestat. Patients should be monitored for dermatologic reactions throughout the course of treatment and managed as clinically indicated. For Grade 3 dermatologic reactions, nirogacestat should be withheld until resolved to Grade ≤ 1 or baseline, then it should be restarted at a dose of 100 mg twice daily. Ovarian toxicity Ovarian toxicity was reported in female patients of childbearing potential receiving nirogacestat. Ovarian toxicity, identified based on abnormal reproductive hormone levels or peri‑menopausal symptoms, was reported in 75% of women of childbearing potential receiving nirogacestat in the DeFi study. Ovarian toxicity has been reported to resolve in 79% of women of childbearing potential during treatment. Follow up information is available for all but two out of 27 patients; after stopping treatment, ovarian toxicity was reported to resolve in all women of childbearing potential for whom data are available. Effects of nirogacestat on human fertility are unknown. Based on findings from animal studies, female fertility may be impaired. Women of childbearing potential should be advised about the risk of ovarian toxicity before initiating treatment with nirogacestat. Patients should be monitored for changes in menstrual cycle regularity or the development of symptoms of oestrogen deficiency, including hot flashes, night sweats, and vaginal dryness. Electrolyte abnormalities Electrolyte abnormalities, including hypophosphataemia and hypokalaemia, were reported in patients receiving nirogacestat. Phosphate and potassium levels should be monitored regularly and supplemented as necessary. For Grade 3 hypophosphataemia persisting for ≥ 7 days despite maximal replacement therapy, nirogacestat should be withheld until resolved to Grade ≤ 1 or baseline, then it should be restarted at a dose of 100 mg twice daily. For Grade 3 hypokalaemia of any duration, despite maximal replacement therapy, nirogacestat should be withheld until resolved to Grade ≤ 1 or baseline, then it should be restarted at a dose of 100 mg twice daily. Hepatic abnormalities ALT or AST elevations were reported in patients who received nirogacestat. Liver function tests should be monitored regularly. For ALT or AST ≥ 3 to 5 x ULN, nirogacestat should be withheld until ALT, AST, or both are resolved to < 3 x ULN or baseline, then it should be restarted at a dose of 100 mg twice daily. For ALT or AST > 5 x ULN, nirogacestat should be permanently discontinued (see section 4.2). Non‑melanoma skin cancers Non‑melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) were reported in patients receiving nirogacestat. Skin examinations should be performed prior to initiation of nirogacestat and routinely during treatment with nirogacestat. Cases should be managed according to clinical practices and patients may continue with nirogacestat treatment without dose adjustment. Embryo‑foetal toxicity – Contraception in males and females Nirogacestat may cause foetal harm when administered to a pregnant woman. Patients should be advised of the potential risk to a foetus. Women of childbearing potential must have a negative pregnancy test prior to initiating nirogacestat treatment. Pregnancy testing during treatment with nirogacestat should be considered for women of childbearing potential experiencing amenorrhoea. Women of childbearing potential receiving nirogacestat must use highly effective contraceptive methods during treatment with nirogacestat and for 1 week after the last dose of nirogacestat. Women of childbearing potential should be advised to inform their healthcare provider immediately of a known or suspected pregnancy, and they must stop taking nirogacestat if they become pregnant. Male patients with female partners of childbearing potential should be advised to use highly effective contraceptive methods during treatment with nirogacestat and for 1 week after the last dose of nirogacestat. About SpringWorks Therapeutics SpringWorks Therapeutics, a healthcare company of Merck, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We developed and are commercializing the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). We are also advancing a portfolio of novel targeted therapy product candidates for patients with additional rare tumors and hematological cancers. For more information, visit and follow @SpringWorksTx on X, LinkedIn, Facebook, Instagram and YouTube. About Merck Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries. Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service. Contacts: Media [email protected] References Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: News and Perspectives. Pathologica . 2021;113(2):70-84. doi:10.32074/1591-951X-213. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol . 2017;29(4):268-274. doi:10.1097/CCO.0000000000000374. van Broekhoven DLM, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol . 2015;22(9):2817-2823. doi:10.1245/s10434-015-4632-y. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer . 2020;127:96-107. doi:10.1016/ Eurostat. Population structure and ageing. European Commission. Accessed June 12, 2025. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol . 2017;29(4):268-274. doi:10.1097/CCO.0000000000000374. Constantinidou A, Scurr M, Judson I, Litchman C. Clinical presentation of desmoid tumors. In: Litchman C, ed. Desmoid Tumors. Springer; 2012:chap 2. Accessed June 12, 2025. Bektas, M, et al. Desmoid tumors: a comprehensive review. Adv Therapeutics. 2023. Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care? Support Care Cancer . 2019;27(3):965-980. doi:10.1007/s00520-018-4386-8. Gounder MM, Maddux L, Paty J, Atkinson TM. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer . 2020;126(3):531-539. doi:10.1002/cncr.32555. Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc . 2017;92(6):947-964. doi:10.1016/ Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg . 1989;210(6):765-769. doi:10.1097/00000658-198912000-00012. OGSIVEO. EMA. Summary of product characteristics (SmPC). SpringWorks Therapeutics, Inc. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer . 2020;127:96-107. doi:10.1016/ Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed June 12, 2025. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Johns Hopkins Health System selects Talkdesk for contact center enhancement
Johns Hopkins Health System selects Talkdesk for contact center enhancement

Business Upturn

time18 hours ago

  • Business Upturn

Johns Hopkins Health System selects Talkdesk for contact center enhancement

PALO ALTO, Calif., and BALTIMORE, Aug. 18, 2025 (GLOBE NEWSWIRE) — Talkdesk, Inc. today announced that Johns Hopkins Health System has selected the Talkdesk Healthcare Experience Cloud™ to modernize its contact center operations as part of a broader technology initiative. The implementation will leverage the Talkdesk Customer Experience Automation™ (CXA) platform to streamline interactions, enhance service delivery, and support multi-channel patient communications. 'Talkdesk Healthcare Experience Cloud is purpose-built for healthcare and designed to help organizations improve operational efficiency and service quality,' said Tiago Paiva, chief executive officer and founder of Talkdesk. The Talkdesk Healthcare Experience Cloud will provide Johns Hopkins Health System with artificial intelligence (AI)-powered self-service , intelligent routing , and omnichannel engagement capabilities. The platform will securely integrate with and embed agent tools within Epic, the organization's electronic health record (EHR) system. Talkdesk participates in Epic's Workshop co-development program, enabling close alignment between contact center workflows and electronic health record functionality. About Talkdesk Talkdesk® is leading a new era in customer experience with Customer Experience Automation (CXA)—a new category and platform designed to automate the full complexity of modern customer journeys. CXA replaces fragmented, human-coordinated workflows with autonomous, multi-agent AI orchestration that delivers intelligent, scalable, and outcome-focused service across the entire CX lifecycle. At the core of CXA is the Talkdesk Data Cloud, which turns transcripts, call recordings, case notes, and customer records from across CRMs and systems of record into real-time, actionable knowledge. This enables AI agents to operate with full context, collaborating seamlessly to resolve complex customer problems with speed, precision, and adaptability. Talkdesk CXA supports both cross-industry workflows and industry-specialized use cases in sectors like healthcare , financial services , retail , utilities , travel , and government . With prebuilt AI agents, a virtuous automation cycle (Discover, Build, Orchestrate, Measure), and rapid time-to-value, Talkdesk helps enterprises modernize customer experience without the need for a full rip-and-replace. Trusted by global brands and recognized for continuous innovation, Talkdesk empowers organizations to grow revenue, reduce costs, and transform service delivery through coordinated, AI-driven automation. Companies that love their customers use Talkdesk. Talkdesk is a registered trademark of Talkdesk, Inc. Epic is a registered trademark of Epic Systems Corporation. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. Media Contact: Talkdesk Public Relations [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store